Press Releases Percheron Therapeutics Limited

Equities

PER

AU0000317281

End-of-day quote Australian S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
0.077 ^AUD	0.00%		+20.31%	+30.51%

Feb. 28	Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI
2023	Dimerix Appoints Nonexecutive Chair	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets	22-08-23	GL
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets	22-08-22	GL
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets	22-08-22	AQ
New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2	22-06-22	GL
New Muscle Disease Indication for ATL1102 – Limb Girdle Muscular Dystrophy R2	22-06-22	AQ
Antisense Therapeutics : Prospectus	22-04-11	PU
Antisense Therapeutics to present poster at world’s largest NMD conference	22-03-09	GL
Antisense Therapeutics to present poster at world’s largest NMD conference	22-03-09	GL
Antisense Therapeutics : Application for quotation of securities - ANP	22-01-27	PU
Antisense Therapeutics : Quarterly Report and Appendix 4C	22-01-26	PU
Antisense Therapeutics : Application for quotation of securities - ANP	21-12-23	PU
Antisense Therapeutics : Application for quotation of securities - ANP	21-12-21	PU
Antisense Therapeutics : Annual General Meeting Presentation	21-12-14	PU
Antisense Therapeutics : Update - Proposed issue of securities - ANP	21-11-23	PU
Antisense Therapeutics : Morgans rates ANP as Add	21-07-01	AQ
Antisense Therapeutics : Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website	20-06-11	BU
Antisense Therapeutics : ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints	20-05-21	BU
Antisense Therapeutics : Announces Appointment of US-based Consultant Medical Director	20-02-26	BU
Antisense Therapeutics : Appointment of Non-Executive Director (G Pace)	15-11-08	PU
Antisense Therapeutics : ATL1103: Data Presentation at the Society for Endocrinology BES 2015 Conference	15-11-03	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Percheron Therapeutics Limited

Equities

PER

AU0000317281

Press Releases

Filters